If you’re unfamiliar with V2X, it was created through the July 5, 2022, reverse merger of publicly-traded Vectrus Inc. and privately-owned The Vertex Company. The combination created a company ...

Bank of America Securities analyst Mariana Perez Mora maintained a Hold rating on V2X (VVX – Research Report) today and set a price target of ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective increased by Bank of America from $555.00 to $567.00 in a research note issued on Monday,Benzinga reports.